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Overview of the p21-Activated Protein Kinases
P21-ACTIVATED PROTEIN KINASES (PAKs) are serine/threonine kinases that execute a multitude of cellular and physiological functions. PAK1, the prototype of the family, was initially discovered in 1994 as a novel effector of small GTPases (114) . PAKs have been extensively studied as part of numerous intricate and interconnecting signaling networks that regulate important cellular activities, including cell proliferation, apoptosis, and cytoskeleton dynamics (15, 20, 59, 122) . Both the disarrangement of the Pak1 gene and the dysfunctions of PAK signaling under pathophysiological conditions have been identified, particularly for their involvement in tumorigenesis and cancer metastasis (44, 97) . The potential role of PAK signaling in the development and progression of neuronal diseases, viral pathogenesis, and immunity, as well as vascular disorders, have been suggested as well (54, 75, 86, 87, 96, 127, 133, 189) . In addition to the aforementioned functions of PAKs, there is emerging evidence implicating the importance of PAKs in metabolic processes, specifically in glucose homeostasis. PAK1 was found to mediate the effect of insulin on stimulating glucose uptake in skeletal muscle cells, in facilitating insulin secretion in pancreatic ␤-cells, and in controlling the production of the incretin hormone glucagon-like peptide-1 (GLP-1) in the gut endocrine L cells (29, 74, 84, 181, 195, 196) .
Here we summarize the functions of PAKs, mainly focusing on the emerging roles of PAK1 in glucose homeostasis. We have reviewed the studies to date in the exploration of the molecular and cellular functions of PAK1 in the muscle, pancreatic ␤-cells, and intestine endocrine L cells, which collectively point to an essential metabolic role of PAK1. These studies have also deepened our functional understanding of the PAK family, and continued efforts in this field may lead to the discovery of novel drug targets for type 2 diabetes (T2D) and other metabolic disorders.
The discovery of PAKs, their structural features, and the activation mechanism. Guanine nucleotide binding proteins (G proteins) act as molecular switches that transmit a wide variety of extracellular stimuli to intracellular signaling cascades. The majority of the G proteins fall into two categories, namely the monomeric forms (small GTPases) and the heterotrimeric membrane-bound complexes (Fig. 1A) . Small GTPases are able to bind to and hydrolyze guanosine triphosphate (GTP).
The Ras superfamily of small GTPases comprises over 150 members. It is further classified into eight families (Fig. 1A) . One of them is the Ras homologous (Rho) family, whose members are also referred to as p21 GTPases since their molecular sizes are ϳ21 kDa. Within the Rho family, PAKs have been identified as downstream effectors of the members of Rac and Cdc42 subfamilies but not for members of the RhoA subfamily (Fig. 1A) .
PAK1 was discovered as a binding partner and target of Rac and Cdc42 GTPases in the rat brain in 1994 and was originally named p65PAK (114) . The autophosphorylation and kinase The group I PAK proteins share a common autoinhibitory domain (AID, black). Members of group I PAKs also contain acid-rich domains known as ED-rich regions (light blue) as well as a noncanonical PXP Pix/Cool SH3-binding motif (dark blue) in the central region. C: illustration of the PAK1 molecule. The small p21 GTPases, including Rac, Cdc42, CHP, TC10, and Wrch-1, bind to the PBD (orange) and stimulates its activation. Ser21, Ser57, Ser144, Ser149, Ser199, Ser204, and Thr423 areactivity of p65PAK were shown to be stimulated in the presence of activated Cdc42 and Rac, and sequence analysis of p65PAK revealed its homology with the yeast protein Ste20 (114) . p65PAK was later renamed as PAK1, while the other two members of the family were designated as PAK2 and PAK3 (15, 16, 118, 175) . Together, these three kinases comprise the group I PAKs (Fig. 1B) . After the initial discovery of PAK1-3, three additional PAKs, namely PAK4 -6, were identified in mammals (73) . They differ significantly from group I PAKs in their structural organization and regulation and are referred to as group II PAKs (Fig. 1B) (47, 73) . PAK4 was identified as a novel link between Cdc42 and actin cytoskeleton, where activated PAK4 can be translocated into the Golgi and induced fibroblast filopodia formation and actin polymerization (1). PAK6 was identified as an androgen receptor (AR) interacting protein, and was suggested to serve as a negative regulator of the androgen/AR signaling (204) . PAK5 is a brain kinase that promotes neurite growth and filopodia formation (37) .
All PAK members share the NH 2 -terminal p21 binding domain (PBD) and the highly conserved COOH-terminal catalytic kinase domain (KD) (Fig. 1B) . A unique feature of the group I PAKs is the autoinhibitory domain (AID), which overlaps but is not coincident with the PBD. The AID acts as an "inhibitory switch" and is critical for the autoinhibition of group I PAKs. Group I PAKs also possess proline-rich PXXP and PXP SH3-binding motifs interspersed at the NH 2 terminus and central regions. On the other hand, in the group II PAKs, these SH3-binding motifs are only found in the central region (Fig. 1B) . In the PAK1 molecule, these proline-rich motifs interact with the Rac1/Cdc42 activator Pix/Cool (PAK interactive exchange partner/Cloned out of library), as well as certain adapter proteins, such as Nck and Grb2 (21, 115, 141) .
As the most extensively studied member of the PAK family, the crystal structure of PAK1 in an autoinhibited conformation was determined in 2000 (100) . The currently accepted mechanism of group I PAK activation is a multistage model, where binding of Cdc42 or Rac to the PBD domain disrupts PAK-PAK dimerization, leading to a series of conformational changes that destabilize the folded structure of the inhibitory switch and thereby inducing the dissociation of the two PAK molecules (100) . Once freed from each other, the individual PAK molecule may undergo sequential autophosphorylation steps leading to its full activation.
PAK1 contains seven autophosphorylation sites (Fig. 1C ) (113) . Shortly after the discovery of PAK1, the Thr423 residue located within the activation loop was identified to act as a critical determinant of PAK1 activation by p21 GTPases and the lipid sphingosine (209) . The T423A PAK1 mutant, which is unable to be autophosphorylated at this residue, showed substantially reduced kinase activity following Cdc42 activation (209) . With the use of biochemical methods, PAK1 autophosphorylation at Thr423 was demonstrated to occur as an intermolecular event, where an active PAK1 can trans-autophosphorylate another PAK1 molecule (92) . Since then, PAK1 Thr423 phosphorylation, assessed by Western blotting using commercially available antibodies, has served as an indicator of its activation in numerous studies (29, 45, 52, 111, 126, 135, 164, 197, 199, 212) .
Positive and negative regulators of PAK1. Multiple positive and negative regulators of PAK1 have been identified (Fig. 2) . Other than Rac1 and Cdc42, PAK1 can also be activated by certain atypical Rho members, including CHP, TC10, and Wrch-1 (3, 156, 162, 172) (Fig. 2) . The CHP/PAK1/PIX signaling has been shown to regulate cell adhesion during zebrafish embryonic development (174) . TC10 was found to activate PAK1 in assessing insulin-stimulated prolactin gene expression in the rat pituitary GH4 cells (162) . Wrch-1 is a Wnt-1-stimulated small GTPase, which stimulates PAK1 Thr423 phosphorylation in the COS-7 cell line (172) .
PAK1

Hormones
Positive regulators
Negative regulators In addition to these small GTPases, other proteins including tumorigenic factors, growth factors, and hormones, have been demonstrated to activate PAK1 (Fig. 2) . Thrombin-stimulated PAK1 activation was observed in vascular smooth muscle cells, and expression of the kinase-dead PAK1 mutant was shown to attenuate stress fiber formation and cell migration (193) . The epidermal growth factor (EGF) stimulates PAK1 activation in breast cancer cells, and expression of a dominantnegative PAK1 was shown to attenuate EGF-induced cell migration (205) . PAK1 serves as a convergence point for platelet-derived growth factor (PDGF) and lysophosphatidic acid in regulating collagen matrix contraction in human fibroblasts (146) . Overexpression of PDGF is known to stimulate Erk activity in medulloblastoma cells, and this was found to be mediated through the PAK1-MEK-Erk signaling cascade (208) . PAK1 was also shown to mediate the function of estrogen in stimulating FKHR phosphorylation, leading to FKHR nuclear exclusion and the inhibition of cell apoptosis (119) . Notably, the growth factor insulin-like growth factor-1 (IGF-1), as well as the metabolic hormone insulin, were found to activate PAK1 as well (Fig. 2) . IGF-1 activates RUNX2, a transcription factor that promotes endothelial cell migration, invasion, and proliferation. PAK1 inhibition attenuates RUNX2 DNA-binding (142 Several endogenous negative regulators of PAK1 have also been recognized ( Fig. 1C and Fig. 2 ). The skeletal muscle and kidney enriched inositol phosphatase (SKIP) binds to the KD of PAK1 and inhibits its scaffolding activity (66) . Merlin, encoded by the Nf2 tumor-suppressor gene, inhibits PAK1 activation by targeting its PBD (93) . The serine threonine kinase LKB1 phosphorylates PAK1 at Thr109, leading to its inactivation (39) . The cysteine-rich inhibitor of PAK (CRIPAK), identified in a yeast two-hybrid screen, was shown to suppress PAK1-mediated estrogen receptor transactivation in breast cancer cells (170) . The integrin binding partner Nischarin inhibits PAK1 activity and PAK1-mediated cell migration through its direct interaction with the PAK1 COOH-terminal domain (2) . The human G␤-like WD-repeat protein (hPIP1) binds to the PAK1 NH 2 -terminal regulatory domain, which abolishes Cdc42/Racstimulated PAK1 activity (202) .
The mechanisms underlying Pak1 transcriptional regulation remain largely unknown, although the increase in Pak1 gene copy number has been reported in certain tumor cells (22, 129) . One study has demonstrated that the microRNA miR-7 binds to the 3=-untranslated region of Pak1 mRNA and may repress Pak1 expression in human carcinoma cells (145) .
An overview of cellular functions of PAK1. Here, we present a brief overview of the cellular functions of PAK1 (Fig. 3 ). An extensive body of knowledge exists for the downstream effects of PAK signaling, which have been described in detail elsewhere (9, 20, 26, 44, 59, 122) . PAK1 exerts its prosurvival and antiapoptotic functions via a battery of downstream targets, including Raf1, NFB, FKHR, BimL, and DLC1 (17, 35, 48, 51, 119, 188) (Fig. 3, column 1) . PAK1 is centrally involved in cytoskeleton remodeling, either by phosphorylating kinases that regulate actin dynamics, such as LIMK, or by phosphorylating factors and kinases that are involved in actin-based cell motility, such as myosin light chain (MLC), myosin heavy chain (MHC), and MLC kinase (MLCK) (24, 28, 33, 36, 144, 152, 190, 199, 201, 210) (Fig. 3, column 2) . In mast cells, PAK1 was shown to directly interact with and activate the phosphatase PP2A in regulating F-actin rearrangement and mast cell granulation (163) (Fig. 3, column 2 ). Mast cells from PAK1 Ϫ/Ϫ mice showed abnormal cortical F-actin structures and granules and impaired allergic responses (163) . The effectors of PAK1 in regulating cell cycle progression are listed in Fig. 3, column 3 , including the mitotic regulators cyclin D1, NF-B, Aurora, and Polo-like 1 (PlK1) (17, 35, 117, 211) , the chromatin protein component histone H3 (99) , and the components of the mitogen-activated protein kinase cascade MEK1 and Raf1 (18, 50, 91, 171, 180) . The targets that mediate the function of PAK1 in regulating immune functions and hostpathogen responses are listed in Fig. 3 , column 4. PAK1 activates Nck and Erk during T-cell activation, and PAK1 phosphorylates CtBP1 during adenovirus entry (6, 105, 149, 203) (Fig. 3, column 4) . Finally, PAK1 is increasingly recognized to participate in nuclear events in regulating gene transcription and mRNA splicing (Fig. 3 , column 5). Three nuclear localization signals have been identified in the PAK1 NH 2 terminus, which are required for its nuclear translocation (158) . In the nucleus, PAK1 modulates transcriptional regulators, such as FKHR, CtBP, SHARP, and Snail, and directly regulates chromatin rearrangement through its interaction with histone H3 (101) . Notably, PAK1 has been shown to enhance the transcriptional activity of the nuclear Wnt effector ␤-cat in carcinoma and noncarcinoma cells (112, 134) .
Loss-of-function and gain-of-function studies of PAK1 and other PAKs.
The association between PAK activity and tumorigenesis or metastasis has been intensively investigated (26, 90, 97, 130) . The underlying mechanisms include increased Pak gene copy numbers, hyperactivation of the kinase activity, dysregulation of upstream regulators, or enhanced nuclear localization of PAKs (8, 22, 60, 90, 116, 151, 187) . Many studies have been conducted using loss-of-function approaches, such as dominant-negative forms of PAK1, RNA interference, or chemical inhibitors (27, 49, 108, 134, 164) . During the recent years, several small molecule inhibitors of PAKs have been identified with varying degrees of specificity (38, 90, 103, 106) . Among these, the chemical inhibitor 2,2=-dihydroxy-1,1=-dinaphthyldisulfide (IPA3) has demonstrated high specificity towards the inhibition of group I PAKs (38) .
Gain-of-function approaches have also been utilized in a number of studies. The expression of various forms of constitutively active PAK1 resulted in the formation of larger lamellipodia and increased mobility of fibroblasts (154) . The T423E constitutively active PAK1 mutant has been used in studying cell proliferation (134, 153, 177) , tumorigenesis (27, 72, 108) , and viral pathogenesis (82, 136) . Pak1 Ϫ/Ϫ mice are viable, with various degrees of defects in their immune, neuronal, pulmonary, and cardiac systems (5, 13, 61, 88, 110, 120, 159, 169) . In the absence of a challenge, fasting plasma glucose levels in Pak1 Ϫ/Ϫ mice are comparable with those of the control littermates. However, in the presence of a glucose or pyruvate challenge, impaired glucose disposal was observed in the Pak1 Ϫ/Ϫ mice (29, 195) . Pak2 Ϫ/Ϫ mice are embryonic lethal at embryonic day 8.5 (9, 59) . The PAK3 gene in humans is associated with X-linked nonsyndromic mental retardation (9, 59) , and the Pak3 Ϫ/Ϫ mice show deficits in memory retention (121) . Pak1 and Pak3 double knockout mice show severely reduced postnatal brain growth, associated with other neuronal deficits (63) . Pak4 Ϫ/Ϫ mice are embryonic lethal at embryonic day 11, while Pak4 Ϫ/Ϫ embryos were found to carry defects in neuronal differentiation and blood vessel formation (143) . Conditional knockout of Pak4 specifically in the nervous system resulted in neuronal defects, along with striking differences in brain anatomy in neonatal mice (178) . Lastly, both the Pak5 Ϫ/Ϫ mice and the Pak6 Ϫ/Ϫ mice are viable, and the gross morphology of various organs appears to be normal (104, 124) . It has been suggested that this may be due to the potential redundant functions of PAK5 and PAK6 (104) . A comprehensive review on Pak knockout mouse models has been presented recently by Kelly and Chernoff (88) .
Role of PAK1 in Glucose Transport in the Skeletal Muscle
In 1996, Tsakiridis et al. (181) revealed the presence of insulin-responsive renaturable kinases in the mouse differentiated L6 muscle cells. Using histone VI-S as the substrate, Tsakiridis et al. (181) found that insulin is able to stimulate the activity of PAK1. Utilizing chemical inhibitors for various cell signaling molecules, Tsakiridis et al. (181) concluded that insulin-stimulated PAK1 activation is dependent on the tyrosine kinase activity and the activity of phosphoinositide 3-kinase (PI3K).
Insulin-stimulated glucose uptake by skeletal muscle cells is a key process in maintaining glucose homeostasis, and this is accomplished by the recruitment of GLUT4 vesicles to the plasma membrane. Actin cytoskeleton reorganization is involved in insulin-stimulated GLUT4 vesicle translocation, as pharmacological agents that disrupt actin dynamics, such as latrunculin B, inhibited GLUT4 translocation to the plasma membrane and led to reduced glucose uptake in the muscle cells (23, 31, 166, 183) . Insulin is known to regulate actin dynamics in cultured muscle cells and in the mouse L6 myotubes (179, 182) . The binding of insulin to the insulin receptor results in the phosphorylation of the insulin receptor substrate-1 (IRS-1), which in turn recruits and activates PI3K. The insulin signaling cascade bifurcates at PI3K into two arms consisting of Rac1 and Akt (150) . Insulin-induced actin cytoskeleton reorganization in muscle cells requires PI3K activity (94, 183, 184) , and insulin-stimulated GLUT4 translocation and actin remodeling can be blocked either by depleting Rac1 or by inducing conditions that mimic insulin resistance in cultured muscle cells (74, 185) . Expression of a constitutively active Rac1 elicited GLUT4 vesicle translocation even in the absence of insulin, suggesting that the presence of active Rac1 suffices in stimulating GLUT4 translocation, at least in the in vitro setting (185) . Treating cultured muscle cells with glucose oxidase mimics insulin resistance in vitro, and this leads to the inhibition of Rac1 activation, accompanied by the loss of Rac1-mediated PAK1 Thr423 phosphorylation (74) . These observations highlighted the requirement of Rac1 signaling in insulin-stimulated muscle glucose uptake, involving the process of cytoskeleton remodeling. Consistent with the observations made in the above in vitro investigations, insulin was demonstrated to stimulate Rac1 activation in mouse skeletal muscle, and mice with muscle-specific deletion of Rac1 show reduced insulin-induced GLUT4 vesicle translocation in the muscle tissue (186) .
Another small GTPase, namely RalA, has been reported to function as the effector of Rac1 in mediating its stimulatory effect on muscle glucose uptake. Depletion of RalA using the small interfering RNA-mediated knockdown approach was shown to reduce Rac1-stimulated GLUT4 vesicle plasma membrane translocation in the mouse L6 myotubes (128).
Observations described above indicated the essential role of Rac1 in mediating the stimulatory effect of insulin on GLUT4 membrane translocation and that PAK1 is among the downstream targets of insulin and Rac1 in the muscle. The generation of Pak1 Ϫ/Ϫ mice made the direct assessment of the contribution of PAK1 in muscle glucose uptake available. Following insulin injection, muscle samples collected from Pak1 Ϫ/Ϫ mice showed significantly reduced GLUT4 vesicle translocation to the plasma membrane, when compared with the muscle samples from age-matched wild-type littermates (195) . Cofilin has been reported to act downstream of the PAK1 effector LIMK and is critically involved in the regulation of actin filamentsin a marsupial kidney epithelial cell line (40) . In line with the role of PAK1/LIMK/cofilin signaling in cytoskeletal reorganization in epithelial cells, the skeletal muscle from Pak1 Ϫ/Ϫ mice was shown to lack the response to insulin treatment in stimulating cofilin phosphorylation (195) .
A very recent study by Sylow et al. (166) provided extended evidence that Rac1-PAK1 signaling centrally regulates muscle glucose uptake in intact muscle tissue. More importantly, this signaling axis was rendered defective under the insulin-resistant state (166) . First, they demonstrated that insulin indeed stimulates Rac1 and PAK1 activation in both mouse and human skeletal muscle (166) . Pharmacological inhibition of Rac1 resulted in the loss of insulin-stimulated glucose uptake, independent of Akt status, in isolated mouse skeletal muscle (166) . Muscle-specific deletion of Rac1 in mice resulted in reduced insulin-stimulated muscle glucose uptake, associated with attenuated insulin-stimulated PAK1 Thr423 phosphorylation in the muscle (166) . Importantly, skeletal muscle isolated from high-fat diet-fed mice showed reduced Rac1 expression, associated with blunted PAK1 Thr423 phosphorylation in response to insulin treatment (166) . These observations in the experimental animals were at least partially recapitulated in humans, where skeletal muscle insulin resistance induced via intralipid infusion resulted in a loss of insulin-stimulated PAK1 Thr423 phosphorylation during a hyperinsulinemic-euglycemic clamp study (166) .
Similar to PAKs, the Rho-associated coiled-coil-containing protein kinases (ROCKs) are serine/threonine kinases that also act as downstream effectors of certain small GTPases, and ROCKs have been shown to participate in insulin signaling and energy homeostasis (62) . Inhibition of ROCK1 impaired GLUT4 translocation, while ROCK1 overexpression lead to an enhanced insulin-sensitizing effect on glucose transport in adipocytes (34) . In the myoblasts, ROCK1 depletion lead to attenuated insulin-stimulated glucose transport, associated with defects in actin cytoskeleton remodeling (34) . Taken together, these observations indicate the involvement of additional small GTPase effectors, such as ROCKs, in GLUT4 translocation and glucose transport in the muscle (34, 62, 74) .
In addition to insulin activation, muscle contraction represents another mechanism by which muscle glucose uptake can be stimulated (55) . The activity of Rac1 was observed to be elevated during contraction-stimulated glucose uptake in skeletal muscle, and this was concomitant with enhanced PAK1 Thr423 phosphorylation (167) . PAK activation and muscle glucose uptake following contraction were attenuated by either Rac1 inhibition or the use of F-actin depolymerizing agents in vitro, as well as in muscle-specific Rac1 Ϫ/Ϫ mice (166, 167) . Furthermore, PAK1 Thr423 phosphorylation was enhanced in mouse and human skeletal muscle following exercise, whereas lipid infusion in healthy volunteers impaired PAK1 Thr423 phosphorylation. These observations collectively suggest that Rac/PAK1 signaling plays a role in muscle glucose disposal during exercise (166, 167) .
As aforementioned, Akt2 is another arm of insulin signaling after its bifurcation at PI3K (150) . In 2002, a 160-kDa substrate of Akt was identified in 3T3L1 adipocytes, known as AS160 (85) . It is a protein that contains a Rab GTPase-activating protein (GAP) domain. Upon insulin stimulation, Akt2 transmits the signal to AS160, which in turn activates the small GTPases Rab8A and Rab13, and ultimately induce GLUT4 vesicle release (71, 165) . Both the Rac1 arm and the Akt2 arm upregulate glucose uptake in the skeletal muscle, and it has been proposed that each arm act independently of each other in promoting GLUT4 vesicle translocation (150, 168) . Furthermore, the joint requirement of both arms in insulin-stimulated GLUT4 translocation has been suggested, where pharmacological inhibition of both Akt2 and Rac1 signaling cascades was shown to be required to completely block insulin-stimulated glucose uptake in mouse muscle cells (168) . In addition, both Akt2 and Rac1 signaling pathways were found to be dysfunctional in the muscle tissue of the insulin-resistant ob/ob mouse model (168) . Interestingly, in examining the involvement of PAK1 as the effector of Rac1 signaling, muscle tissue isolated from Akt2 Ϫ/Ϫ mice appear to have blunted insulin-stimulated PAK1 Thr423 phosphorylation, while pharmacological inhibition of Akt2 does not alter PAK1 activation (168) . To explain this obvious discrepancy, it has been proposed that although the Rac1 and Akt2 arms do not cross talk with each other in regulating glucose uptake, the presence of Akt2 is still required for the activation of the Rac1 cascade (168) .
The essential role of Rac1 in regulating actin dynamics underlying muscle glucose uptake has been demonstrated in numerous investigations (31, 74, 150, 185) . Although PAK1 has been shown to regulate actin filament dynamics in a number of other cell types, including neuronal cells and pancreatic ␤-cells (detailed in the sections below) (57, 98, 140, 163) , the direct effect of PAK1 on actin remodeling in muscle cells remains to be examined.
Role of PAK1 in Insulin Secretion
Following food consumption or glucose stimulation, insulin is released from pancreatic ␤-cells in two distinct phases, known as biphasic insulin secretion. The first phase is triggered by the elevation of intracellular calcium levels, leading to the fusion of predocked insulin-containing granules to the plasma membrane. The second phase involves the mobilization of stored granule pools to the cell surface, which represents the sustained insulin release following glucose stimulation.
As demonstrated by Wang et al. (196) , Cdc42/Rac1 signaling is evidently involved in the insulin secretion process, as Cdc42 knockdown selectively attenuated the second phase of glucose-stimulated insulin secretion (GSIS) in rodent pancreatic ␤-cell lines and in isolated mouse and human pancreatic islets. In the mouse pancreatic ␤-cell line MIN6, Cdc42 acti-vation was detected in response to D-glucose treatment but not to potassium chloride (KCl) or the nonmetabolizable glucose analogs (196) . Furthermore, Cdc42 activation in response to high glucose treatment preceded Rac1 activation at the plasma membrane, and PAK1 Thr423 phosphorylation was observed to be Cdc42-dependent but Rac1 independent (196) . Knockdown of PAK1 expression in the mouse ␤-cell line using the small interference RNA knockdown approach abolished Cdc42-mediated Rac1 activation (196) . These observations collectively implicate the existence of the Cdc42-PAK1-Rac1 axis during the second phase of GSIS in the pancreas (196) , which differs from the Cdc42-Rac1-PAK1 signaling observed in the skeletal muscle cells in terms of the sequential order of activation of the signaling components (74) .
To further assess the role of PAK1 in insulin secretion and to explore its pathophysiological implications, Wang et al. (195) conducted further investigations. They demonstrated that PAK1 protein levels are reduced in islets of T2D patients (195) . In human islets and a rodent pancreatic ␤-cell line, IPA3 pretreatment was shown to elicit a defect in the second phase of GSIS (195) . Wang et al. (195) then revealed that Pak1 Ϫ/Ϫ islets exhibited attenuated second phase of GSIS, associated with impaired glucose and insulin tolerance in the Pak1 Ϫ/Ϫ mice. To identify downstream effectors of PAK1 during GSIS, Wang et al. (195) performed PAK1 small interference RNA knockdown in a pancreatic ␤-cell line and observed an abolished glucose-induced Erk activation. This event was also partially recapitulated in pancreatic islets isolated from the Pak1 Ϫ/Ϫ mice (195, 196) . Although PAK1 has been widely accepted as a positive regulator of cell proliferation, the Pak1 Ϫ/Ϫ mice lack notable defects in pancreatic ␤-cell mass and abnormalities in islet morphology, as observed by both Wang et al. (195) and by our group (29) .
The importance of F-actin remodeling in GSIS has been recognized for Ͼ40 yr, where F-actin filaments were shown to act as barriers at the plasma membrane to prevent the docking and fusion of insulin granules under unstimulated conditions (14, 131, 191) . Rac1 and a number of other small GTPases have been implicated in various functions of pancreatic ␤-cells, including the secretion of insulin at different steps (95) . In a murine ␤-cell line, Rac1 activation was shown to be stimulated by high glucose treatment (102) . The expression of a dominant-negative Rac1 in ␤-cells abolished its cytosol-to-membrane translocation upon high glucose stimulation, which was associated with reduced GSIS (102). Very recently, Asahara et al. (12) demonstrated the role of Rac1 in regulating GSIS via modulating F-actin using both in vitro and in vivo approaches. In the pancreatic ␤-cell line MIN-6, Rac1 activation was observed following high glucose treatment (12) . Rac1 knockdown leads to the persistence of intact F-actin in the presence of high glucose, associated with reduced insulin secretion following glucose stimulation (12) . The study utilizing islets isolated from ␤-cell-specific Rac1 Ϫ/Ϫ mice also recapitulated the observations of defective insulin secretion following high glucose treatment, without significant alterations in islet morphology (12) .
Although PAK1 is evidently involved in the second phase of GSIS, the exact mechanism by which PAK1 evokes F-actin remodeling in response to glucose is still not completely understood. An early study identified the role of the Cdc42-PAK1-Rac1 axis in regulating F-actin rearrangement and insulin secretion in ␤-cells (196) . It was further demonstrated that glucose-induced cortical F-actin remodeling also involves the Cdc42-PAK1-MEK-Erk pathway and that glucose-induced insulin granule exocytosis can be blocked by the PAK inhibitor IPA3 (83, 84) . The downstream effects of the PAK1-MEK-Erk signaling cascade may include MLCK, an actin-associated kinase that has been implicated in ␤-cell insulin secretion (11, 83) .
In a recent live cell imaging study, Kalwat et al. (84) have further elucidated the mechanistic requirement of PAK1 in glucose-stimulated insulin granule exocytosis. Pretreatment of mouse pancreatic ␤-cells with IPA3 inhibited glucose-induced F-actin remodeling and ablated glucose-stimulated insulin granule localization to the plasma membrane (84) . In mouse ␤-cells, glucose treatment stimulated Raf1 phosphorylation and activation, while IPA3 treatment or Cdc42 inhibition abolished this activation (84) . Similarly, IPA3 treatment blunted MEK to Erk signaling, while the presence of a MEKErk inhibitor disrupted F-actin remodeling and resulted in defective insulin granule release (84) . Altogether, these in vitro findings implicate the functional requirement of PAK1 in relaying the signal of Cdc42 to the downstream Raf1-MEKErk cascade, which potentiates insulin granule mobilization through F-actin remodeling (84) .
Despite the substantial evidence supporting the notion that Cdc42-PAK1 signaling participates in insulin granule mobilization, the effect is still needed to further clarify how Cdc42 activation, in response to high glucose treatment, leads to PAK1 activation in pancreatic ␤-cells The synapses of amphids defective (SAD-A) kinase is a serine/threonine kinase closely related to the AMP-activated kinases (4) . SAD-A is exclusively expressed in the brain and pancreas and has been implicated in synaptic function and neuronal development (68) . In examining the role of SAD-A in insulin secretion, Nie et al. (126) first showed that treatment with high glucose induces SAD-A activation and SAD-A can stimulate PAK1 Thr423 phosphorylation and PAK1 kinase activity in a murine pancreatic ␤-cell line. SAD-A was also shown to interact with recombinant GST-PBD of PAK, which can be completely abolished by a point mutation that inactivates the SAD-A kinase activity (126) . Overexpression of SAD-A led to enhanced cortical F-actin formation, while expression of a kinase-dead SAD-A K48M mutant induced cortical actin filament disintegration (126) . Importantly, short hairpin RNAmediated SAD-A knockdown attenuated GSIS in the mouse ␤-cell line MIN-6, and adenoviral expression of either K48M SAD-A or the dominant-negative PAK1 mutant K299R was able to significantly reduce GSIS in mouse islets (126) . Taken together, SAD-A is at least among the direct upstream activators of PAK1 in regulating insulin granule exocytosis in ␤-cells. SAD-A has been postulated as the downstream effect of PKA and calmodulin-dependent protein kinase kinase (CaMMK) (126) , while the relationship between SAD-A and Rac1 remains to be investigated. implicated an association among obesity, metabolic syndrome, and the development of various types of tumors, including those in the mammary gland and the large intestine (7, 19, 157, 192, 200) . It has been postulated that the molecular basis for this association is the aberrant insulin signaling, resulting in the stimulation of cell proliferation and tumorigenesis in the context of T2D (43, 109, 164, 198) . The canonical Wnt signaling pathway positively regulates cell proliferation, and its dysregulated activation is strongly associated with tumors of various origins. The clinical and epidemiological correlations between T2D and the cancer risk have been summarized in numerous excellent review articles (42, 46, 69, 70, 77, 79, 81, 132, 160) .
Activation of the canonical Wnt signaling pathway occurs upon the binding of a Wnt ligand to the Frizzled receptor and low-density lipoprotein receptor-related protein 5 and 6 (LRP5/ 6), the coreceptor of the Wnt ligands. This triggers a series of signaling events, ultimately leading to the nuclear translocation of free ␤-catenin (␤-cat) (78) . Nuclear ␤-cat will subsequently interact with a member of the TCF transcription factor family, forming the bipartite transcription factor ␤-cat/TCF. Among the four known TCF members, TCF7L2 has been recognized as an important diabetes risk gene (56) . A number of proproliferative genes, such as c-Myc and cyclin D1, are known downstream targets of ␤-cat/TCF. In addition, our group has demonstrated that ␤-cat/TCF positively regulates the expression of the proglucagon gene (gcg) in the gut endocrine L cells. PAK1 has been shown to serve as a downstream effector of insulin and IGF-1 (89, 142, 147, 181) . In both breast cancer and colon cancer patients, increased PAK1 copy number has been reported (22, 129) . In addition, the upregulation of PAK activity has been associated with the progression and metastasis of various types of tumors (26, 90, 97, 130) . It is therefore plausible to propose that PAKs may act as the linker between insulin/IGF-1 and Wnt signaling pathways. In supporting this hypothesis, a battery of in vitro investigations conducted by our group and others have shown that PAK1 mediates the stimulatory effect of insulin on the proliferation of intestinal tumorous and nontumorous cells, involving the ␤-cat/TCF transcriptional activity (29, 89, 147, 164) .
Both insulin and IGF-1 were shown to stimulate PAK1 Thr423 phosphorylation in different cell lineages (29, 147, 164, 181) , and we have demonstrated that intraperitoneal injection of insulin in the FVB mice resulted in insulinstimulated PAK1 Thr423 phosphorylation in the liver, fat, heart, as well as small and large intestines (164) . In the intestinal carcinoma cell lines, expression of dominant-negative K299R PAK1 attenuated insulin-stimulated c-Myc and cyclin D1 protein expression, while expression of constitutively active T423E mutant PAK1 increased c-Myc and cyclin D1 protein levels following insulin stimulation (164) . The expression of K299R dominant-negative PAK1 also led to reduced insulin-stimulated binding of ␤-cat/TCF to the human c-Myc gene promoter (164) . Furthermore, PAK1 knockdown resulted in a drastic reduction of c-Myc and cyclin D1 expression, accompanied by attenuated Erk1/2 phosphorylation in the presence and absence of insulin stimulation (164) . Finally, insulin treatment was shown to increase ␤-cat phosphorylation at Ser675, an event that is positively correlated with ␤-cat nuclear translocation and ␤-cat/TCF transcriptional activity (58, 164, 173) . In contrast, PAK1 knockdown attenuated insulin-stimulated ␤-cat Ser675 phosphorylation, associated with reduced binding of ␤-cat to the c-Myc gene promoter, and repressed c-Myc gene expression (164) . Recently, in vitro biochemical studies have demonstrated a direct interaction between PAK1 and ␤-cat, where PAK1 was shown to stimulate ␤-cat Ser675 phosphorylation in breast cancer and colon cancer cells (10, 213) . These findings collectively implicate that mechanistically PAK1 acts as a linker between insulin and Wnt signaling pathways.
Role of PAK1 in Proglucagon Gene Expression, GLP-1 Production, and Secretion
The role of Wnt signaling pathway in metabolic homeostasis has captured our attention during the last decade (30, 79) . Hence, we have been exploring the metabolic effect of the cross talk between Wnt and insulin signaling pathways (125, 155, 206, 207) .
The proglucagon gene (gcg) is expressed in pancreatic ␣ cells, intestinal endocrine L cells, and certain neuronal cells in the brainstem. The gcg gene encodes several important peptide hormones, including the incretin hormone GLP-1, which is mainly produced in the gut and brain but not in the pancreas (25) . Lithium treatment, which mimics Wnt ligand activation (161) , was shown to stimulate gcg transcription and GLP-1 synthesis in the intestinal L cells, while the expression of a dominant-negative TCF7L2 abolished lithium-induced gcg transcription and GLP-1 production. More recently, we found that the Wnt ligand Wnt3a can also stimulate gcg promoter activity and increase gcg mRNA levels in the mouse intestinal endocrine L cell line GLUTag (29) . Although insulin was shown to repress gcg expression in pancreatic ␣-cells (137, 138) , it activates gcg transcription in the gut GLP-1-producing cells, and this activation was found to be PI3K dependent but Akt independent (207) . Furthermore, insulin treatment was shown to stimulate gcg promoter activity, and this stimulation depends on the TCF binding motif within the G2 enhancer element. The G2 enhancer element is known to mediate ␤-cat/ TCF-or Wnt ligand-stimulated gcg promoter activity. Indeed, insulin treatment enhanced binding of ␤-cat/TCF7L2 to the G2 enhancer element (207) . Thus the cross talk between insulin signaling and the Wnt signaling pathway effectors ␤-cat/ TCF7L2 represents a novel mechanism underlying the transcriptional regulation of gut gcg expression and GLP-1 production (76) .
Considering that PAK1 functions as a mediator for the cross talk between insulin and Wnt signaling pathways in the gut endocrine and nonendocrine cells as well as elsewhere (147, 164) , we asked whether PAK1 plays a role in regulating gut and brain gcg expression and GLP-1 production. We first of all verified that insulin treatment indeed stimulates PAK1 Thr423 phosphorylation in both the mouse intestinal endocrine L-cell line GLUTag and a hypothalamic gcg-expressing neuronal cell line (29) . We then found that insulin treatment also stimulated ␤-cat Ser675 phosphorylation in these two cell lines (29) . In the GLUTag cell line, IPA3 was shown to block the stimulation of insulin on ␤-cat Ser675 phosphorylation, associated with attenuated gcg promoter activity and gcg mRNA expression following insulin stimulation (29) . We then expanded the investigation to investigate the physiological implications of PAK1 in GLP-1 production and function utilizing the Pak1 glucose as well as pyruvate challenge (29) . Furthermore, Pak1 Ϫ/Ϫ mice show drastically lower levels of intestinal and brain gcg mRNA, associated with reduced distal ileum GLP-1 content, and decreased circulating insulin and GLP-1 levels following oral glucose challenge (29) . These in vivo observations demonstrated that PAK1 ablation leads to the impairment of glucose homeostasis, as well as defective insulin and GLP-1 responses following glucose challenge (29) . As PAK1 regulates gut gcg expression, the reduction in gut gcg expression in the Pak1 Ϫ/Ϫ mice likely contributes, at least partially, to the overall glucose intolerance (29) .
In the intestinal endocrine L cells, PAK1 was also verified to be the target of Cdc42, where Cdc42 and PAK are required for insulin-induced actin remodeling (107) . In the mouse gut GLUTag cell line, chemical reagents that disrupt filamentous actin potentiated GLP-1 secretion, whereas the knockdown of either Cdc42 or PAK1 attenuated actin remodeling and GLP-1 secretion (107) . Hence, activation of the Cdc42/PAK1 signaling cascade and the consequent actin remodeling events also positively regulate GLP-1 secretion, at least in the in vitro setting (107) .
Summary, Disputes, and Perspectives
Originally identified as effectors of selected small GTPases including Cdc42 and Rac1, the PAK family of protein kinases have been shown to carry out a plethora of functions in various cell lineages, including cell proliferation and apoptosis, cytoskeleton remodeling, cell cycle progression, and gene transcription. The exploration of these general cellular functions of PAKs, especially its prototype PAK1, has been further expanded into the field of metabolic research, revealing the fundamental role of PAK1 in glucose homeostasis during health and disease. PAK1 is expressed in multiple metabolic tissues, and it evidently functions as an important metabolic regulator. A schematic overview of the current knowledge on the role of PAK1 in glucose homeostasis is presented in Fig. 4 , focusing on its role in glucose uptake in the skeletal muscle, in insulin secretion in the pancreatic islets, and in the production and function of the incretin hormone GLP-1 in the intestine.
Upon food intake, the rise in plasma glucose levels leads to the postprandial release of insulin. The insulin/IRS-1/PI3K signaling not only activates Akt2, which utilizes AS160 and Rab proteins to stimulate glucose uptake (176) , but also activates the Cdc42-Rac1-PAK1 signaling axis in regulating GLUT4 vesicle translocation (Fig. 4, left) . Actin remodeling is a key process underlying GLUT4 vesicle translocation, which provides the mechanistic basis for glucose uptake. The Rac1/ PAK1 signaling plays a fundamental role in insulin-stimulated GLUT4 vesicle mobilization, and deficiency of either Rac1 or PAK1 leads to impaired glucose uptake in response to insulin stimulation. However, it remains unclear as to whether PAK1, or other downstream effectors of Rac1, or both, mediate the actin remodeling events in the skeletal muscle cells. In addition, the relationship between the contributions of PI3K-Akt2 signaling vs. PI3K-Rac1-PAK1 signaling in muscle glucose uptake in response to insulin or exercise needs to be further explored.
It should be pointed out that, although the majority of studies to date have focused on assessing PAK1 in the muscle as a protein kinase, one laboratory has recently suggested a potential novel mechanism for PAK1 in regulating glucose uptake (66) . The inositiol phosphatase SKIP has been shown to inhibit insulin/PI3K/Akt signaling and repress insulin-stimulated GLUT4 translocation as well as glucose uptake in the mouse L6 myoblasts (64, 65, 67) . It has been postulated that the underlying mechanism involves the binding of SKIP to PAK1, which blocks PAK1 scaffolding function but not its kinase activity in mouse myoblasts (66) . Hence, the potential dual function of PAK1 in insulin-stimulated muscle glucose uptake is worth furtherer exploration.
In pancreatic ␤-cells, the elevation of plasma glucose stimulates postprandial insulin release, and the underlying mechanisms include the activation of the Cdc42-Rac1-PAK1 signaling cascade in the ␤-cells, and the secretion of the gut incretin hormones, including GLP-1 (Fig. 4, right and middle) . Depletion or knockdown of Cdc42 or PAK1 abolished the second phase of GSIS in the rodent pancreatic ␤-cell line as well as in mouse and human islets (195, 196) . In line with these in vitro findings, Pak1 Ϫ/Ϫ mice were shown to exhibit reduced plasma insulin levels following glucose challenge (29, 195) .
As aforementioned, the role of PAK1 as a scaffold has been demonstrated in muscle cell glucose uptake (66) . A very recent investigation further showed that overexpression of a kinasedead PAK1 in Hela cells and in the colon cancer cell lines led to increased MEK and Erk phosphorylation, without affecting the phosphorylation status of PAK1 downstream targets (194) . In pancreatic ␤-cells, whether the scaffolding function of PAK1 participates in regulating insulin secretion remains an open question.
It should be noted that the hierarchical relationship between PAK1 and the small GTPases could be cell type or tissue specific. Both the Cdc42-PAK1-Rac1 axis and the Cdc42-PAK1-Raf1-MEK-Erk axis have been demonstrated to participate in the regulation of GSIS in pancreatic ␤-cells (196) . In the skeletal muscle cells, as presented in Fig. 4 , left, PAK1 was shown to act downstream of both Cdc42 and Rac1 in regulating insulin-stimulated glucose uptake (74) . In addition to the varying sequence of activation events, the functions of Cdc42 and Rac1 have been found to vary in other cell lineages. Cdc42 and Rac1 have been demonstrated to act in antagonistic manners, in the generation of reactive oxygen species (41) , and in the regulation of cell proliferation (32, 123) .
Finally, in the gut endocrine L cells, PAK1 was shown to regulate both the production and secretion of GLP-1 (29, 107) (Fig. 4, middle) . PAK1-deficient mice express reduced levels of gcg mRNA in their gut and brain (29) . We have revealed that PAK1 links insulin with the Wnt signaling pathway effector ␤-cat, leading to the activation of gcg expression and GLP-1 production in the gut GLP-1-producing cell line GLUTag (29) .
As GLP-1 functions as an incretin, it is difficult to evaluate the deleterious effect of PAK1 deficiency in the gut endocrine L cells vs. PAK1 deficiency in the pancreatic ␤-cells on insulin secretion in the Pak1 Ϫ/Ϫ mice. To properly dissect the metabolic function of PAK1 in the gut endocrine L cells vs. the pancreatic ␤-cells, it will be necessary to generate cell type specific knockout animal models.
In addition to the skeletal muscle, pancreatic islets, and intestines, PAK1 is also expressed in tissues including the brain, liver, heart, and adipocytes, all of which are fundamentally involved in metabolic and glucose homeostasis (29) .
Whether PAK1 in those tissues is also involved in regulating glucose homeostasis under physiological and pathophysiological conditions is an interesting direction for future research.
The subtle structural differences among the three members of group I PAKs (Fig. 1B) suggest that they may exert both unique and overlapping functions. It is notable that the metabolic defects observed in the Pak1 Ϫ/Ϫ mice are not drastic. We have noticed that the impairment in whole body glucose disposal was absent when the Pak1 Ϫ/Ϫ mice are in the C57BL/ 6 -129 hybrid background (29) . Even after the Pak1 Ϫ/Ϫ mice have been backcrossed to the C57BL/6 genetic background, in the absence of glucose challenge, the basal blood glucose levels were comparable between the Pak1 Ϫ/Ϫ mice and the control littermates, as demonstrated by our group and by Wang and colleagues (29, 195) . It is reasonable to speculate that certain metabolic functions of PAK1 in the Pak1 Ϫ/Ϫ mice are compensated by the other two group I PAKs. Indeed, redundant functions of PAK1 and PAK3 have been observed in the brain neurons (53, 63) . Hence, it will be imperative to explore and define the unique contributions of each of the three group I PAKs, as well as their redundant functions, with continued in vitro and in vivo investigations.
Mechanistic exploration of the involvement of PAK1 in metabolic homeostasis represents an expansion of our fundamental knowledge of the general cellular functions of PAK proteins. The investigations conducted exploring their role in cytoskeleton remodeling led us to appreciate the role of PAK1 in muscle cell glucose uptake and in ␤-cell insulin secretion. . A summary of current knowledge on the role of PAK1 in glucose homeostasis. Upon feeding, the rise in blood glucose level leads to elevated circulating insulin levels. In the muscle, insulin stimulates GLUT4 translocation via the phosphoinositide 3-kinase (PI3K)-Cdc42-Rac1-PAK1 signaling axis and the PI3K-Akt-AS160 axis in promoting muscle glucose uptake (left). In the pancreas, increased blood glucose level elicits the postprandial release of insulin form the ␤-cells, involving the Cdc42-PAK1-Rac1 signaling cascade (right). The postprandial insulin response is augmented by the incretin hormone glucagon-like peptide-1 (GLP-1; middle). In the gut L cells, insulin activates the PAK1-␤-cat signaling pathway, leading to the stimulation of gcg transcription and GLP-1 production.
The studies deciphering their role in regulating gene expression prompted us to examine the role of PAK1 in gut gcg expression and GLP-1 production. In the cancer research field, PAKs have been shown to function as effectors of growth factors, and they are evidently involved in stimulating cell proliferation and inhibiting cell apoptosis. In the Pak1 Ϫ/Ϫ mice, we, however, did not observe noticeable proliferative defects in the pancreatic ␤-cells and elsewhere (29) . Again, this suggests that the other two group I PAKs may compensate the function of PAK1 in the Pak1 Ϫ/Ϫ mice. Hence, we will need to employ both gain-of-function and loss-of-function approaches, under both in vitro and in vivo settings, to further elucidate whether and how members of group I PAKs play redundant roles in controlling ␤-cell proliferation. It should be pointed out that PAK3 may coordinate the stress response (148) . A very recent study indicated that PAK3 stimulates cell cycle exit and differentiation of embryonic pancreatic ␤-cells (139) . PAK3 is essential for maintaining glucose homeostasis in response to high-fat diet challenge (139) . Hence, group I PAK members may exert not only redundant and compensatory function but also opposite functions in pancreatic ␤-cells. This is worthy of further investigation.
In summary, extensive in vitro and in vivo investigations to date have uncovered that PAK1 exerts critical functions in the muscle, pancreas, and gut in regulating glucose disposal. Future exploration, including the expansion of the study into other PAK members as well as additional metabolic tissues, will aid in our understanding of the complex regulatory networks underlying glucose homeostasis during health and disease.
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